Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab vs mycophenolate for relapsing NMOSD (China, phase 4)
ChiCTR2600119728Phase 4Completed
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Relapse-free rate. Started Mar 2026; status: completed.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on ChiCTR2600119728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119728.